• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

戈舍瑞林致化学性烧伤:一例病例报告及文献复习

Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature.

作者信息

Mahadevan Aditya, Warnecke Brian, Chiao Elaine, Nafissi Nellie, Parajuli Kritisha, Rijal Nejina, Parajuli Ritesh

机构信息

Department of Hematology and Oncology, University of California Irvine School of Medicine, Orange, USA.

Department of Hematology and Oncology, University of California Irvine Medical Center, Orange, USA.

出版信息

Cureus. 2023 Sep 21;15(9):e45692. doi: 10.7759/cureus.45692. eCollection 2023 Sep.

DOI:10.7759/cureus.45692
PMID:37745751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10513001/
Abstract

A chemical burn resulting from luteinizing hormone-releasing hormone agonists (LHRHa) is a rare adverse effect that has not been well-documented in prior literature. In this case report, we report a partial-thickness burn that developed following a single subcutaneous injection of goserelin. To our knowledge, this is the first description of goserelin-induced chemical burn in the literature. The importance of early identification and treatment of LHRHa-associated cutaneous reactions must be highlighted to ensure optimal oncologic management and patient comfort.

摘要

促黄体生成素释放激素激动剂(LHRHa)导致的化学灼伤是一种罕见的不良反应,既往文献中对此记载不多。在本病例报告中,我们报告了一例单次皮下注射戈舍瑞林后发生的浅二度烧伤。据我们所知,这是文献中对戈舍瑞林诱导的化学灼伤的首次描述。必须强调早期识别和治疗LHRHa相关皮肤反应的重要性,以确保最佳的肿瘤管理和患者舒适度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece5/10513001/8a518e55e6b1/cureus-0015-00000045692-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece5/10513001/4fede173a6e2/cureus-0015-00000045692-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece5/10513001/8a518e55e6b1/cureus-0015-00000045692-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece5/10513001/4fede173a6e2/cureus-0015-00000045692-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece5/10513001/8a518e55e6b1/cureus-0015-00000045692-i02.jpg

相似文献

1
Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature.戈舍瑞林致化学性烧伤:一例病例报告及文献复习
Cureus. 2023 Sep 21;15(9):e45692. doi: 10.7759/cureus.45692. eCollection 2023 Sep.
2
Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.黄体生成素释放激素激动剂对现代辅助乳腺癌化疗后卵巢功能的影响:GBG 37 ZORO 研究。
J Clin Oncol. 2011 Jun 10;29(17):2334-41. doi: 10.1200/JCO.2010.32.5704. Epub 2011 May 2.
3
Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women.使用促黄体生成素释放激素激动剂抑制卵巢功能治疗绝经前激素受体阳性早期乳腺癌
Front Oncol. 2021 Sep 14;11:700722. doi: 10.3389/fonc.2021.700722. eCollection 2021.
4
An update on ovarian suppression/ablation.卵巢抑制/切除的最新进展。
Int J Gynecol Cancer. 2006;16 Suppl 2:511-4. doi: 10.1111/j.1525-1438.2006.00683.x.
5
[Study on the effects of gonadotropin-releasing hormone analogues in the inhibition of ovarian cancer transplanted tumors and in the protection of ovarian function after chemotherapy on nude mice].[促性腺激素释放激素类似物对裸鼠卵巢癌移植瘤的抑制及化疗后卵巢功能保护作用的研究]
Zhonghua Fu Chan Ke Za Zhi. 2011 Dec;46(12):892-7.
6
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.绝经前激素受体阳性转移性乳腺癌患者使用阿那曲唑加戈舍瑞林治疗的 II 期临床试验。
J Clin Oncol. 2010 Sep 1;28(25):3917-21. doi: 10.1200/JCO.2009.24.9565. Epub 2010 Aug 2.
7
Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.近距离放射治疗前单独使用比卡鲁胺可实现细胞减灭,这与促黄体生成素释放激素类似物相似,但患者报告的发病率较低。
Urol Oncol. 2008 Jul-Aug;26(4):372-7. doi: 10.1016/j.urolonc.2007.05.014. Epub 2008 Jan 8.
8
Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies.化疗中使用促黄体生成素释放激素激动剂抑制卵巢功能以保留乳腺癌患者的卵巢功能和生育能力:一项随机研究的荟萃分析。
Ann Oncol. 2015 Dec;26(12):2408-19. doi: 10.1093/annonc/mdv374. Epub 2015 Sep 7.
9
Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin)--lack of shrinkage of uterine fibroids.他莫昔芬在接受促黄体生成素释放激素激动剂(戈舍瑞林)治疗的女性中的雌激素作用——子宫肌瘤无缩小
Fertil Steril. 1989 Dec;52(6):924-9. doi: 10.1016/s0015-0282(16)53153-7.
10
Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.促黄体生成激素释放激素类似物与他莫昔芬联合用于激素受体阳性绝经前乳腺癌女性的辅助治疗。
Expert Opin Pharmacother. 2017 Sep;18(13):1357-1362. doi: 10.1080/14656566.2017.1363181. Epub 2017 Aug 10.

本文引用的文献

1
Erythema nodosum caused by goserelin acetate sustained-release: Case report and literature review.醋酸戈舍瑞林缓释植入剂致结节性红斑:病例报告并文献复习。
Int J Rheum Dis. 2023 Oct;26(10):2055-2059. doi: 10.1111/1756-185X.14692. Epub 2023 Apr 28.
2
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.绝经前早期乳腺癌患者化疗中药物性卵巢抑制的长期结局。
J Natl Cancer Inst. 2022 Mar 8;114(3):400-408. doi: 10.1093/jnci/djab213.
3
Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women.
使用促黄体生成素释放激素激动剂抑制卵巢功能治疗绝经前激素受体阳性早期乳腺癌
Front Oncol. 2021 Sep 14;11:700722. doi: 10.3389/fonc.2021.700722. eCollection 2021.
4
Toxic epidermal necrolysis-like toxic erythema of chemotherapy: 2 illustrative cases.化疗所致中毒性表皮坏死松解症样中毒性红斑:2例说明性病例
JAAD Case Rep. 2021 Jul 26;15:56-59. doi: 10.1016/j.jdcr.2021.07.010. eCollection 2021 Sep.
5
Localized Injection-site Toxic Erythema of Chemotherapy: An Under-recognized Acquaintance Revisited.化疗所致局限性注射部位毒性红斑:重新审视一个未被充分认识的情况
Acta Derm Venereol. 2021 Apr 12;101(4):adv00429. doi: 10.2340/00015555-3791.
6
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.一项在 HR 阳性、HER2 阴性的绝经前晚期乳腺癌女性中,联合使用阿培利司或玻玛西林与他莫昔芬加戈舍瑞林的 Ib 期研究。
Clin Cancer Res. 2021 Jan 15;27(2):408-417. doi: 10.1158/1078-0432.CCR-20-1008. Epub 2020 Jul 27.
7
Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs.促性腺激素释放激素类似物治疗乳腺癌
Front Oncol. 2019 Oct 1;9:943. doi: 10.3389/fonc.2019.00943. eCollection 2019.
8
Managing side effects in adjuvant endocrine therapy for breast cancer.管理乳腺癌辅助内分泌治疗的副作用。
Expert Rev Anticancer Ther. 2018 Nov;18(11):1101-1112. doi: 10.1080/14737140.2018.1520096. Epub 2018 Sep 21.
9
Isolated subcutaneous sarcoid-like granulomatous inflammation occurring at injection sites: 3 patients treated successfully with minocycline.注射部位出现的孤立性皮下结节病样肉芽肿性炎症:3例患者用米诺环素成功治疗。
JAAD Case Rep. 2017 Feb 4;3(1):74-77. doi: 10.1016/j.jdcr.2016.12.004. eCollection 2017 Jan.
10
Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trials.绝经前乳腺癌患者卵巢切除或抑制的效果:一项随机对照试验的荟萃分析
Eur J Surg Oncol. 2017 Jul;43(7):1161-1172. doi: 10.1016/j.ejso.2016.11.011. Epub 2016 Dec 5.